SGLT2i Reduce Arrhythmic Events in Heart Failure Patients with Cardiac Implantable Electronic Devices
Marco Valerio Mariani(Sapienza University of Rome), Carmine Dario Vizza(Sapienza University of Rome), Agostino Piro(Sapienza University of Rome), Marta Palombi(Sapienza University of Rome), Vincenzo Myftari(Sapienza University of Rome), Nicola Pierucci(Policlinico Umberto I), Silvia Prosperi(Sapienza University of Rome), Cristina Chimenti(Policlinico Umberto I), Paolo Severino(Sapienza University of Rome), Carlo Lavalle(Sapienza University of Rome), Domenico Laviola(Sapienza University of Rome), Sara Trivigno(Sapienza University of Rome), Vincenzo Mirco La Fazia(University of Rome Tor Vergata), Pietro Cipollone(Sapienza University of Rome), Andrea D’Amato(Sapienza University of Rome), Domenico Filomena(Sapienza University of Rome), Josefina Magliolo(Sapienza University of Rome), Roberto Badagliacca
Cited by 32
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
|The Journal of Heart and Lung Transplantation|2020|207
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
|Journal of the American College of Cardiology|2024|137
Acute Kidney Injury Resulting From Hemoglobinuria After Pulsed-Field Ablation in Atrial Fibrillation
|JACC. Clinical electrophysiology|2024|103
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
|International Journal of Molecular Sciences|2018|99